Retatrutide at 40mg represents a intriguing development in the field of size reduction. The drug is a new dual modulator targeting both glucagon-like peptide-1 sites (GLP-1) and glucose-dependent insulinotropic polypeptide targets. Preliminary human studies have shown considerable reductions in p